Responses
Regular and young investigator award abstracts
Clinical trials in progress
402 DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone
Compose a Response to This Article
Other responses
No responses have been published for this article.
